Radiology Question for the Week of February 13, 2017



What are the HCPCS codes for ISOVUE® (Iopamidol Injection)?



There are two codes, and the one you report depends on the iodine concentration. Both codes are reported per mL.

  • Report ISOVUE® 200 (Iopamidol Injection 41%) and ISOVUE® 250 (Iopamidol Injection 51%) with the following code:

Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml

  • Report Isovue 300 (Iopamidol Injection 61%) and Isovue 370 (Iopamidol injection 76%) with the following code:

Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml

ISOVUE® (Iopamidol Injection)

Indications and Usage:

Isovue-200, 250, 300, 370
Isovue is indicated for angiography throughout the cardiovascular system, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography (phlebography), and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic (CECT) head and body imaging.

Isovue IS NOT FOR INTRATHECAL USE. Iopamidol Injection is available as Isovue-M® for intrathecal administration.

Nonionic iodinated contrast media inhibit blood coagulation, in vitro, less than ionic contrast media. Clotting has been reported when blood remains in contact with syringes containing nonionic contrast media. Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary, particularly during angiographic procedures, to minimize thromboembolic events.

As with all injectable contrast agents, the possibility of severe reactions should be borne in mind, regardless of the patient’s pre-existing medical history. As with any other iodinated contrast media, caution must be exercised in patients with severely impaired renal function, combined renal and hepatic disease, combined renal and cardiac disease, severe thyrotoxicosis, myelomatosis, or anuria, particularly when large doses are administered.

Please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Isovue and Isovue-M are currently manufactured for Bracco Diagnostics Inc. at two locations: BIPSO GmbH, Singen (Germany) and Patheon Italia S.p.A., Ferentino (Italy).

Isovue and Isovue-M are registered trademarks of Bracco Diagnostics Inc